Allergan

Combo UTI drug can now treat costly pneumoniasFDA approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of ceftazidime and avibactam (Avycaz) to include 2 types of pneumonia.
Cosmetic eyeliner tattoo as risk factor for ocular surface diseaseOphthalmology Times is pleased to announce Igor I. Bussel, MD, MS, MHA, and Deepinder K. Dhaliwal, MD (faculty sponsor), of the Department of Ophthalmology, University of Pittsburgh/UPMC Eye Center, Pittsburgh, as the second-place winner of the 2017 Resident Writer’s Award Program, sponsored by Allergan. Their entry is featured here.
Study finds no VA benefit by adding corticosteroid implant to anti-VEGF injections
How MIGS are changing glaucoma treatmentEvolving procedures continue to change the landscape of glaucoma treatments. Chief Optometric Editor Benjamin P. Casella, OD, FAAO, explores how the use of minimally (or micro-) invasive glaucoma surgery (MIGS) techniques can increase positive outcomes when treating glaucoma patients.
Tear osmolarity: Dry eye's 'vital sign'Hyperosmolarity emerges as key mechanism in TFOS DEWS II pathophysiology report
How generic cyclosporine might affect optometry
How generic cyclosporine might affect optometryI foresee every dry eye script I write to be “changed” to generic cyclosporine. This means optometrists will be straddled with more burdensome prior authorizations and delays for the patients.
Using contact lenses to steepen the cornea post surgeryThe over response of LASIK patients is not a common event, but it does happen. CLAPIKS provides a straightforward and practical approach to help patients through this healing period.
Substance P: Dry eye and allergy’s mixed signal or missing link?Inflammation may lead to heightened peripheral sensitization and stimulation through a developing concept in which neuroimmune cross-talk causes the confounding interplay of both signs and symptoms in dry eye and allergic disease.
Targeting dry eye in glaucoma patients
Targeting dry eye in glaucoma patientsA poor ocular surface is a common condition in glaucoma patients due to the incidence of dry eye, age, and use of benzalkonium chloride (BAK). Poor compliance with glaucoma therapy can result. Use of point-of-care testing can help identify patients with a poor ocular surface and drive treatment decisions. Treatment options, including surgical, are discussed.
Uro Pipeline: Supplemental application submitted for advanced RCC treatmentOther pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.